About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020. The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each. The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21. During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020. As on 31 March 2020,the company has one subsidiary and one associate company under its roof. The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator. The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956.. In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022. During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

Suven Pharmaceuticals Ltd Chairman Speech

Dear Shareholders,

With immense satisfaction yet a heavy heart, I ink my last message as Managing Director of Suven Pharmaceutical Limited. We have sold our stake in the Company to Advent International, one of the world's largest and most experienced private equity investors.

I want to take the opportunity to address two questions that may be spawning in your mind.

Why did we sell the stake in the Company? The answer is simple. To ensure that Suven Pharma sustains its commitment to create enormous value for its shareholders. Let me elucidate the thought.

Over the years, we carefully grew our CRAMS business as a part of Suven Lifesciences Limited from a small venture into a globally respected enterprise supporting large companies in their innovation projects. More recently, we spun off the CRAMS business into Suven Pharmaceutical, a strategy that created significant value for our shareholders.

Now Suven Pharmaceutical is a large and globally respected company. To sustain the Company's growth momentum and wealth creation capability, we need to ideate and identify new opportunities that allow us to utilise our core strengths better and will emerge as new growth levers for Suven Pharma. Our divestment has allowed us to bring in new partners who will help in achieving this strategic vision which will significantly enhance the value proposition for stakeholders over the medium term.

Why Advent International? They come in with multi-decadal experience in efficiently managing global-scale enterprises. Other interested investors had also approached us for acquiring the Company, but what tilted the scale in their favour was our shared and aligned vision for Suven Pharma - to graduate the Company into a new orbit of growth and respect with global innovators.

It gives me considerable peace of mind that Suven Pharma, which we had so carefully fostered in the crucible of passion and perseverance, is in the right hands and will be taken forward to greater heights by a like-minded management team.

The new management has the depth of knowledge and the bandwidth of expertise and experience to navigate the Company through the current headwinds and capitalise on growth opportunities over the medium term to deliver immense value to all stakeholders.

The medium-term

The passion and pace of innovation projects, especially in the Western world, are closely dovetailed with economic progress owing to the immense resources deployed. Given the highly turbulent geopolitical situation, economic progress across nations in the current year will be impacted, directly or otherwise. This will decelerate the momentum of ongoing research projects and postpone initiating new projects.

As the vigor of human conflicts diminishes and the world order gravitates towards a more balanced position, innovation intensity will only accelerate. Moreover, the innovation world is moving East owing to the incredible value-proposition provided by the East, especially India.

The opportunities for India, in my opinion, should expand, considering that global innovators are seriously considering a credible alternative to China for supporting them in their innovation journey. While the shift will take time, as there are a plethora of considerations and regulatory challenges in orchestrating a shift between nations and enterprises, I am confident that some relocation will happen over the next 3-4 years.

Suven Pharma is perfectly poised for a brighter tomorrow. We have invested in relevant technologies and capabilities to effectively and efficiently secure opportunities and sustain our success.

As I leave my office with truckloads of successes, experiences, learnings and memories, I look forward to reading about the Company's achievements over the coming years. I wish the new management well and will continue to support them as an advisor for some time.

In closing, I take this opportunity to thank my colleagues on the Board for their continued support in drawing the long-term blueprint for the Company. I thank the Management team for building relevant strategies and executing them flawlessly. I thank the entire Suven Pharma team for their unwavering support in building the organization to where it is now – without their untiring efforts; we would never have made it this far. I also express my sincere gratitude to all other stakeholders for your continuing support. I am sure you will continue supporting the new management in the same manner you backed me.

Warm regards,

Venkat Jasti

Managing Director

Suven Pharmaceuticals Ltd Company History

Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020. The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each. The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21. During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020. As on 31 March 2020,the company has one subsidiary and one associate company under its roof. The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator. The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956.. In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022. During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

Suven Pharmaceuticals Ltd Directors Reports

To the Members of

Suven Pharmaceuticals Limited

Your Company's Board of Directors has pleasure in presenting this 5^th Annual Report together with Ind AS compliant Audited Financial Statements of the Company for the financial year ended 31^st March, 2023.

Financial Performance

( Rs. in lakhs)

Review of Operations

On a standalone basis, during the fiscal 2022-23 under review your Company performed well and recorded revenue of Rs.,33,008 lakhs, higher by 0.75 percent over the previous year's revenue of 1,32,022 lakhs. The Profit after Tax (PAT) of the Company is recorded at Rs. 43,260 lakhs in fiscal 2022-23 registering a decay of (22) percent over the

PAT of 55,810 lakhs in fiscal 2021-22. The Earnings Per Share (EPS) of your Company is at Rs. 16.99 in fiscal 2022-23 per share.

On consolidation basis, the profit after tax (PAT) for Fiscal 2022-23 has gone down to the order of H41,129 lakhs. The Earnings per Share (EPS) of your Company is recorded at H16.16 per share.

The consolidated financial statements of the Company prepared in accordance with Indian Accounting Standards as specified in the Companies (Indian Accounting Standards) Rules, 2015, form part of the Annual Report.

Exports

The exports of the Company remained the major chunk of revenue accounting for Rs.,29,493 lakhs, representing 97% of the total revenue operations of Rs.,33,008 lakhs during the year under review.

Dividend

Your Directors are pleased to inform you that the Board has declared interim dividend of Rs..00 per share and one-time special dividend of Rs. 5.00 per share totaling to Rs..00/- (600%) per equity share of the face value of Rs..00 each on September 02, 2022 and paid to the shareholders in September 2022. The total dividend for the financial year worked out to Rs..00/- (600%) per equity share.

Transfer to Reserves

The Company transferred Rs.,500 lakhs to the general reserve during the current financial year.

Share Capital

The paid up Equity Share Capital as on March 31, 2023 was Rs.,545.65 lakhs. During the year under review, the Company has not issued any shares with differential voting rights nor granted stock options or sweat equity shares.

Annual Return

Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return as on March 31, 2023 is available on the Company's website and can be accessed at web link at https://suvenpharm.com/financial-info/#financialInfosection

Number of Meetings of the Board and Audit Committee

During the year under review six Board Meetings were convened and held and five Audit Committee Meetings were convened and held. The details of Board meetings and Audit Committee meetings are presented in the Corporate Governance report, which forms part of this Annual Report. The Audit Committee composed of independent and non-executive directors. Shri Rs.. G. Prasad is the Chairperson of the Audit Committee and Shri V. Sambasiva Rao and Shri J. V. Ramudu are members of the Audit Committee. The time gap between the said meetings was within the period prescribed under the provisions of the Companies Act, 2013 and the SEBI guidelines thereof.

Directors Responsibility Statement

Your Directors state that:

(a) The applicable accounting standards have been followed in the preparation of the Annual Accounts and there were no material departures.

(b) Such accounting policies have been selected and applied consistently and judgments and estimates made when required that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period.

(c) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

(d) The Directors have prepared the Annual Accounts on a going concern basis.

(e) Proper internal financial controls were in place to be followed by the Company and that the financial controls were adequate and were operating effectively. (f) Proper systems devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

Policy on Nomination & Remuneration

The Board has, on the recommendation of the Nomination & Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration. The Remuneration Policy is stated in the Corporate Governance Report and forms part of this report and is also available on https://www.suvenpharm. com/images/pdf/policies/Remuneration_Policy.pdf

Dividend Distribution Policy

The Board has adopted a suitable Policy for Dividend Distribution as per the requirements of SEBI Guidelines. The policy is stated in the Annual Report and has been uploaded on the Company's website and can be accessed at https://www.suvenpharm.com/images/pdf/policies/ dividend-distribution-policy.pdf

Particulars of Loans, Guarantees or Investments

Details of loans given, investments made, guarantees given and securities provided are furnished in the Standalone Financial Statement which can be referred at Note No. 6 and 31 to the Standalone Financial Statements.

Apart from this, the Company did not give any Loans, investments or provided Guarantees or any security during the year under the provisions of Section 186 of the Companies Act, 2013.

Subsidiary companies

Your Company has one international wholly owned subsidiary company and one Indian wholly owned subsidiary Company as on 31^st March, 2023. The consolidated financial statements of the Company prepared in accordance with Indian Accounting Standards as specified in the Companies (Indian Accounting Standards) Rules, 2015, form part of the annual report.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013, a statement containing salient features of financial statements of subsidiaries in Form AOC-1 is attached to the financial statements of the Company. Further, pursuant to the provisions of Section 136 of the Act, separate audited financial statements in respect of the subsidiary companies shall be kept open for inspection at the Registered Office of the Company during working hours for a period of 21 days before the date of the Annual General Meeting. Your Company will also make available these documents upon request by any Member of the Company interested in obtaining the same. The separate audited financial statements in respect of the subsidiary companies is also available on the website of your Company at https://suvenpharm.com/financial-info/ #financialInfosection

Related Party Transactions

The Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 in the prescribed Form AOC-2 pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014, forms part of this report as "Annexure – A".

The Board has approved a policy for related party transactions and has been uploaded on the Company's website.

Casper Pharma acquisition

During the year, your company has acquired 100% state in Caper Pharma Private Limited, a Hyderabad based SEZ unit in formulations business for a purchase consideration of H15680.45 Lakhs from the seller shareholders and the Company has further invested an amount of H4172.92 Lakhs by way of subscription to the 52,16,156 Rights equity shares of the Casper Pharma in June 2022. The Casper Pharma is now Wholly Owned Subsidiary and the annual accounts of the said subsidiary are consolidated with the Company for the financial year ended 31^st March, 2023. The USFDA inspection of SEZ unit of Casper Pharma Private Limited is completed during the year.

Material Changes and Commitments Affecting Financial Position of the Company

There are no material changes and commitments, affecting the financial position of the Company, which has occurred between the end of the financial year of the Company i.e. March 31, 2023 and the date of the Directors' report i.e. May 25, 2023.

Change in Management

During the year the founder promoters of the company have signed definitive agreement to sell a part of their stake to the extent of 12,75,37,043 equity shares of face value of Rs./- each representing 50.10% of paid up capital of your company to the Acquirer – Berhyanda Limited for a purchase consideration of Rs. 495/- per equity share of face value of Rs./- each. The Acquirer had obtained all statutory approvals such as CCI, Department of Pharmaceuticals under Ministry of Chemicals & Fertilizers of Govt. of India.

The said transaction was consummated on September 29, 2023. Your company's operations will be under new management – Advent International Corporation a USA based private equity fund which has invested in your company through its investment arm Berhyanda Limited a Cyprus based foreign company.

Change in Board of Directors

As there was a change in management pursuant to take over as per SEBI Regulations, the following new Directors were appointed on the Board as Additional Directors in compliance with the applicable provisions of Companies Act, 2013 and SEBI Regulations.

The brief profile(s) of above director(s) seeking appointment at the ensuing Annual General Meeting are presented in the Annual Report.

All the previous Directors have resigned from the Board effective from September 29, 2023 as such there will be no retiring director seeking re-appointment in this 5^th Annual General Meeting of your Company.

Directors and Key Managerial Personnel

The Company did not appoint any Director during the year under review. None of the Directors has resigned during the year under review.

In the opinion of the Board, all the new Independent Directors possess the integrity, expertise and experience including the proficiency required to be Independent Directors of the Company, fulfill the conditions of independence as specified in the Act and the Listing Regulations and are independent of the management and have also complied with the Code for Independent Directors as prescribed in Schedule IV of the Companies Act, 2013.

The Company did not appoint any Key Managerial Personnel during the year under review. None of the Key Managerial Personnel has resigned during the year under review.

Declaration by Independent Directors

All independent directors of the Company have given declarations under Section 149(7) of the Companies Act, 2013 confirming that they meet the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI Listing Regulations and also afirmed compliance with Code of conduct as required under Regulation 26(3) of the Listing Regulations.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The information on conservation of energy, technology absorption, foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of the Companies (Accounts) Rules, 2014, forms part of this report as "Annexure – B".

Risk Management Policy

Your Company has formulated a suitable risk management policy to take care of all aspects of Contract Development and Manufacturing Operations (CDMO) business model of your Company: viz., competitive position, capabilities, various risk covers and risk mitigation preparedness etc. Your Company operates with rich talent pool of scientists having 2 decades of experience in the form of expertise, capability and timely deliverables to global innovators to ensure smooth flow of CDMO projects to sustain steady revenues. In addition, your company regularly conducts safety and preventive audits in all plants and ensures that necessary safeguards are in place to protect the work force and assets against all perils with appropriate insurance policies.

Corporate Social Responsibility

In compliance with Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules 2014, the Company has established Corporate Social Responsibility (CSR) Committee composed of Shri J.V.RamuduasChairperson,Smt.DeepanwitaChattopadhyay, Dr. V. Sambasiva Rao and Shri Venkateswarlu Jasti as members. The CSR programs of the Company are being implemented by Suven Trust. As of 31^st March, 2023 there were no amounts due payable to Suven Trust by your Company. In accordance with the amended rules your company does not require to undertake the impact assessment of CSR projects.

Annual Report on CSR Activities forms part of this Report as "Annexure – C". The CSR Policy, Committee Composition and CSR programs details are available on the Company's website on https://suvenpharm.com/csr/csr-policy/

Performance Evaluation of the Board

Pursuant to the provisions of the Companies Act, 2013 and as per the SEBI (LODR) Regulations, 2015, the Board has carried out an annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working of its Committees. The Independent Directors separately carried out evaluation of Chairperson, Non Independent Directors and Board as a whole. The performance of each committee was evaluated by the Board, based on views received from respective committee members. The manner in which the evaluation has been carried out has been explained in the Corporate Governance Report.

Deposits

During the FY 2022-23, the Company has not accepted any fixed deposits, and, as such, no amount on account of principal or interest on deposits was outstanding as on the date of the balance sheet.

Internal Financial Control Systems and their Adequacy

Your Company has laid down set of standards which enables to implement internal financial control across the organization and ensure that the same are adequate and operating effectively (1) to provide reasonable assurances that: transactions are executed in conformity with generally accepted accounting principles/standards or any other criteria applicable to such statements, (2) to maintain accountability for assets; access to assets is permitted only in accordance with management's general or specific authorization and the maintenance of records that are in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; and (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets that could have a material effect on the financial statements. The Audit Committee of the Board reviews the reports submitted by the independent internal auditors and monitors the functioning of the system.

Vigil Mechanism

The Company promotes ethical behavior in all its business activities. Towards this, the Company has adopted a policy on Vigil Mechanism and Whistle Blower to deal with instance of fraud and mismanagement, if any. The details of the Whistle Blower Policy is explained in the Corporate Governance Report and also posted on the website of the Company. https://www. suvenpharm.com/images/pdf/ policies/whistle-blower-policy.pdf

Particulars of Employees and Remuneration

The information required under Section 197(12) of the Act read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, forms part of this report as "Annexure – Rs.".

Corporate Governance

A detailed Report on Corporate Governance prepared in substantial compliance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations,

2015 with the Stock Exchanges together with the Practicing Company Secretary Certificate regarding the compliance of conditions of corporate governance, is presented in a separate section forming part of the Annual Report.

Management's Discussion and Analysis

Management's Discussion and Analysis Report for the year under review, as stipulated under Regulation 34 of the SEBI (LODR) Regulations, 2015, is presented in a separate section forming part of the Annual Report.

Statutory Auditors

Pursuant to the provisions of section 139 of the Companies Act, 2013 and the Rules framed thereunder the Company in its 1^st Annual General Meeting (AGM) held on 30^th November, 2019 has appointed M/s. Karvy & Co., Chartered Accountants (Firm Registration No. 001757S) as statutory auditors for a period of 5 years from the conclusion of 1^st AGM till the conclusion of the sixth AGM to be held in the year 2024. The Companies (Amendment) Act, 2017 dispensed the ratification of auditor's appointment at every Annual General Meeting. The Auditors' Report does not contain any qualifications nor adverse remarks.

Secretarial Auditors

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s. DVM & Associates LLP, Company Secretaries to undertake the Secretarial Audit of the Company. The Secretarial Audit Report forms part of this report as "Annexure – E". The Secretarial Audit Report does not contain any qualifications nor adverse remarks.

Cost Records and Audit

During the year under review, in terms of Cost (Records and Audit) Amendment Rules, 2014 dated 31^st December 2014 issued by the Central Government, the requirement for Cost Audit is not applicable to the Company based on the export turnover criteria prescribed under Cost Audit Rules. However, the Company is maintaining such accounts and record as specified by the Central Government and as applicable to the Company under sub-section (1) of section 148 of the Companies Act, 2013.

Business Responsibility and Sustainability Report

The Business Responsibility and Sustainability Report as required under the SEBI Listing Regulations, describing the initiatives taken by the Company from environment, social and governance perspective, forms part of this report as "Annexure-F".

Employees Stock Option Scheme

The Company grants share-based benefits to eligible employees with a view to attracting and retaining the best talent, encouraging employees to align individual performances with Company objectives, and promoting increased participation by them in the growth of the Company.

Suven Pharma Employee Stock Option Scheme 2020 ("SPL ESOP 2020")

As per the approval given by the shareholders in the AGM held on 14^th September 2020, the Board has been authorized to introduce, offer, issue and provide share-based incentives to eligible employees of the Company and its subsidiaries under the SPL ESOP 2020 scheme. In terms of the scheme the total number of options to be granted are 10,00,000 of face value of Rs./- each.

The nomination and remuneration committee (NRC) has not granted any options under the SPL ESOP 2020 scheme during the year ended 31^st March, 2023. Upon the granting of the options it shall vest in one or more tranches based on the achievement of defined annual performance parameters as determined by the administrator (the NRC). The total number of equity shares to be allotted to the employees of the Company and its subsidiaries under the SPL ESOP 2020 does not cumulatively exceed 1% of the issued capital.

The SPL ESOP 2020 is drawn up in compliance with SEBI (Share Based Employee Benefits) Regulations, 2014, as amended from time to time, and there has been no material change to the plans during the fiscal.

The SPL ESOP 2020 details, including terms of reference, and the requirement specified under Regulation 14 of the SEBI (Share Based Employee Benefits) Regulations, 2014, are available on the Company's website, at www.suvenpharm.com. As the Company has not yet granted any options during the year ended 31^st March, 2023, the details of the options granted, vested and exercised as per SPL ESOP 2020 is not available in the Notes to accounts of the financial statements in this Annual Report.

Transfer of Unpaid and Unclaimed amounts to Investor Education and Protection Fund (IEPF)

Your company will ensure compliance of the applicable provisions of IEPF Rules at appropriate time, since your company is incorporated in the year 2018.

DisclosureinrelationtotheSexualHarassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company has complied with the provisions relating to the constitution of Internal Complaints Committee as specified under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Your Directors further state that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

General

During the FY2023, there is no change in the nature of business of the company or of its wholly owned subsidiaries. There are no other companies that have become or ceased to be your Company's subsidiaries, joint ventures or associate companies during the year.

The Company has complied with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India during the year under review. Your Directors state that no disclosure or reporting is required in respect of the following matters as there were no transactions on these matters during the year under review:

(i) The details of frauds reported by auditors under sub-section (12) of section 143 other than those which are reportable to the Central Government

(ii) The details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status as at the end of the financial year.

(iii) The details of difference between amount of the valuation done at the time of one-time settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof.

(iv) There are no significant material orders passed by the regulators/ courts /tribunals, which would be impact the going concern status of the company and its future operations.

The Board's Report was originally approved on May 25, 2023 and subsequently, revised due to change in the Board of Directors of the Company pursuant to takeover of the controlling interest in the Company.

Acknowledgements

Your Directors wish to place on record their gratitude to Shareholders for the confidence reposed by them and thank all the shareholders, customers, dealers, suppliers and other business associates for their contribution to your Company's growth. The Directors also wish to place on record their appreciation of the valuable services rendered by the executives, staff and workers of the Company.

Your Directors also thank the Central Government and State Government, the Financial Institutions and Banks for their support during the year and we look forward to its continuance.

For and on behalf of the Board of Directors